[go: up one dir, main page]

WO2002069913A1 - Composition dermatologique - Google Patents

Composition dermatologique Download PDF

Info

Publication number
WO2002069913A1
WO2002069913A1 PCT/JP2001/001595 JP0101595W WO02069913A1 WO 2002069913 A1 WO2002069913 A1 WO 2002069913A1 JP 0101595 W JP0101595 W JP 0101595W WO 02069913 A1 WO02069913 A1 WO 02069913A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
skin
acid
agent
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2001/001595
Other languages
English (en)
Japanese (ja)
Inventor
Sakae Shinkai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CLINICAL COSMETIC Co Ltd
Original Assignee
CLINICAL COSMETIC Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLINICAL COSMETIC Co Ltd filed Critical CLINICAL COSMETIC Co Ltd
Priority to JP2002569091A priority Critical patent/JPWO2002069913A1/ja
Priority to PCT/JP2001/001595 priority patent/WO2002069913A1/fr
Publication of WO2002069913A1 publication Critical patent/WO2002069913A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits

Definitions

  • the present invention relates to a composition set for improving skin.
  • the outermost epidermis of human skin is reborn in about 28 days by metabolism.
  • the newly born skin cells which become the epidermis, gradually rise to the surface of the skin while changing the shape in the form of a scrum, and then come off as dirt about 28 days later. I have. Therefore, as long as this metabolism is performed normally, the skin will always remain fresh.
  • Shin Chen Window is a force that keeps itself healthy by changing its rhythm and tempo and disturbing the scrum of cells as it gets older, that is, homeostasis (homeostasis). Will break. The collapse of the homeostasis causes dullness and spots on the skin, and the skin becomes dry and rough.
  • liquid preparations containing fruit acids (fruit acids) such as succinic acid, malic acid, citric acid, lactic acid, glycolic acid and tartaric acid, which are one kind of ⁇ -hydroxy acids (having carboxy and hydroxyl groups), as active ingredients
  • fruit acids such as succinic acid, malic acid, citric acid, lactic acid, glycolic acid and tartaric acid, which are one kind of ⁇ -hydroxy acids (having carboxy and hydroxyl groups)
  • ⁇ -hydroxy acids having carboxy and hydroxyl groups
  • a-hydroxy acid has the effect of exfoliating the stratum corneum, promoting cell regeneration, and whitening.
  • the present invention can be used without discomfort even when the content of ⁇ -hydroxy acid is increased, and furthermore, the metabolic function is assisted without damaging the skin, and the skin is kept beautiful and fresh.
  • the purpose of the present invention is to provide a composition set for improving skin that can be used. Disclosure of the invention
  • the composition set for skin improvement according to the present invention comprises at least one kind of amino acid, hyaluronate, water-soluble collagen, dipotassium glycyrrhizinate, allantoin, Elastin and at least
  • An agent comprising at least one plant extract as its active ingredient, an agent comprising at least one ⁇ -hydroxy acid, allantoin and dipotassium glycyrrhizinate as an active ingredient, a ceramide and
  • the composition was composed of three compositions of the agent C containing at least one plant extract as at least its active ingredient.
  • the amino acid in the preparation is not particularly limited, but as described in Claim 2, at least one selected from the group consisting of glycine, alanine, proline, serine, threonine, arginine, lysine, and glutamic acid. It is preferable to use
  • the plant extract in Agent A is not particularly limited.
  • the monohydroxy acid contained in the agent B is not particularly limited as contained in the agent C.
  • succinic acid, malic acid, citric acid, lactic acid, glycolic acid, tartaric acid It is preferable to use at least one selected from the group consisting of
  • the plant extract in the agent B is not particularly limited.
  • soybean extract, licorice extract, mulberry extract, cinnamon extract, natto extract, saxifrage extract, ⁇ wow / reshi flow extract It is preferable to use at least one selected from the group consisting of gonex and char extract.
  • agent C preferably contains at least a licorice extract as a plant extract, as described in claim 6.
  • the agent A is not particularly limited, but is preferably a geil type.
  • the concentration of amino acids in agent A is particularly high if it can penetrate pores, sweat, and the stratum corneum, and leave dirt, bacteria, cosmetics, and old keratin, etc., while leaving sebum, and lift it up.
  • it is preferably about 2% by weight to 5% by weight, more preferably 3% by weight to 4% by weight / 0 .
  • the B agent is usually a lotion type, but when it contains an oily active ingredient, suspended particles having a particle size of 300 ⁇ (preferably 100 ni) or less containing the oily active ingredient are contained. It may be a dispersed oil-in-water type emulsion.
  • the above-mentioned emulsion is not particularly limited.
  • it can be produced by using a known micro-emulsifier such as a high-pressure homogenizer.
  • the concentration of ⁇ - hydroxy acid in Agent B is not particularly limited, but is preferably about 4% by weight to 10% by weight, more preferably 7% by weight to 8% by weight, based on the total amount of Agent B. That is, if the concentration of the ⁇ -hydroxy acid is too low, the effect of adding the ⁇ -hydroxy acid is insufficient, and if the concentration is too high, the skin may be damaged.
  • ⁇ of the agent is not particularly limited, but is preferably about 4 to 6. That is, the lower the value of 11 is, the higher the effect of 0; If it is too low, it may be too irritating or cause skin damage.
  • the composition for skin improvement according to the present invention is composed of three types of compositions, A-agent, B-agent, and C-agent.
  • Agent A contains at least one amino acid, hyaluronate, water-soluble collagen, dipotassium glycyrrhizinate, allantoin, elastin, and at least one plant extract as at least active ingredients, The remainder is gelled mainly by purified water and a known thickener, and by adding a preservative and the like as necessary.
  • B agents alpha-hydroxy acids as malic acid, seed stone acid, lactic acid, in a total green cholate, comprising 7-8 wt 0/0 of the total, and further allantoin, at least as active ingredients and dipotassium glycyrrhizinate Included, the remainder is mainly purified water, and is a lotion type with ⁇ ⁇ 4 to 6 to which solvents such as alcohol and ⁇ ⁇ regulator are added as necessary.
  • Agent C is composed of ceramide, a small amount of ⁇ -hydroxy acid (malic acid, seed acid, lactic acid, and glycolic acid), sodium hyaluronate, water-soluble collagen, and complex plants (including at least licorice extract and shea extract) And as an active ingredient.
  • composition set for improving skin is used as follows.
  • composition set for skin improvement is configured as described above, and has the following effects.
  • a agent which contains amino acid as an active ingredient reacts with the water-soluble polymer by simply applying the agent to the skin, penetrates into pores, sweat, and the stratum corneum, and removes dirt such as dust, bacteria, cosmetics, and old dead skin while leaving sebum. Wrap it up and let it rise.
  • Agent B it is possible to clean the skin and help the permeation of the active ingredient in Agent B without rubbing the skin or damaging the skin by massaging.
  • the skin can be cleansed with sebum remaining, even if a B agent containing a high concentration of ct-hydroxy acid is applied to the skin, the skin feels less tingling and has excellent usability. There is no damage to them.
  • Agent A contains, in addition to amino acids, sodium hyaluronate, water-soluble collagen, strength D hydrolyzed elastin, dipotassium glycyrrhizinate, allantoin, and plant extract, so that it does not damage the skin and moisturizes it. can do. That is, sodium hyaluronate is a component that fills the space between the binding fibers and the cells of the skin, and has a strong water retention capacity to take the binding water between the cells and maintain the elasticity of the skin. It also has excellent moisturizing properties and keeps the skin smooth and soft.
  • Water-soluble collagen is a type of connective tissue protein present in the dermis of the skin. It forms a film on the skin and gives the skin moisture and flexibility with a high moisture effect.
  • Hydrolyzed elastin ( ⁇ -elastin) is a protein of connective tissue that exists in the dermis together with collagen, and is obtained by enzymatically decomposing elastin that is involved in the prevention of skin and tarmi. Improve elasticity and flexibility.
  • Dipotassium glycyrrhizinate is a component in extracts extracted from Chinese licorice and has anti-inflammatory and anti-allergic effects, and is effective against eczema and dermatitis.
  • Allantoin is a uric acid derivative contained in fin-filled grass, which has an astringent effect on the skin, removes dead wounds, cracks, eczema, etc., cleanses, promotes new tissue formation .
  • the plant extract has moisturizing, blood circulation promotion, anti-inflammation, capillary enhancement, anti-inflammatory effect and so on.
  • the agent contains a high concentration of ⁇ - hydroxy acid, which is composed of malic acid, tartaric acid, lactic acid, and dalycholic acid, it can effectively activate cells of damaged skin. Specifically, malic acid improves stains made with active oxygen. Tartaric acid keeps the skin in favor, reduces bacterial growth and makes the skin more resistant. Lactic acid works on skin keratin, softens skin, increases moisture retention, and protects skin from drying out. Glycolic acid proliferates fibroblasts in the dermis layer of the skin and improves the firmness of the skin.
  • ⁇ - hydroxy acid which is composed of malic acid, tartaric acid, lactic acid, and dalycholic acid
  • the application of the agent C which contains a large amount of vitamins and minerals and promotes metabolism as an active ingredient, is applied over the agent B, so that the metabolism is further promoted.
  • the licorice extract contained in the agent C is effective in detoxification and antiallergic effects, and can be used to improve atopic dermatitis.
  • the extract contained a large amount of vitamin C and amino acids. Exhibits astringent, antioxidant, and ultraviolet absorption properties.
  • a skin-improving thread set composed of agent C was prepared.
  • agent A to the face, wash the face with lukewarm water within 30 seconds, take agent B on the palm of your hand, apply lightly on the skin, and apply agent C after agent B is used.
  • the procedure of application is 3 people in their 20s (A to C), 5 people in their 30s (A to E), 9 people in their 40s (A to I), 5 people in their 50s (A to E), 5 in the 60s (A
  • composition for improving skin of the present invention comprising the three liquid preparations of A preparation, B preparation and C preparation is used, regardless of age, considerable skin improvement can be achieved in one month of use, regardless of age. The effect is seen, and it is clear that most people will have beautiful skin after 12 months.
  • the present invention is not limited to the above-described embodiments and examples, and that a vitamin supplement component, a fragrance, a solubilizer, a thickener, a humectant, a humectant, a solvent, and the like are contained in each composition.
  • Ingredients to be added to ordinary cosmetics can be appropriately added to such an extent that the function of the active ingredient is not hindered.
  • it goes without saying that it is diluted with purified water.
  • composition set for skin improvement according to the present invention is constituted as described above, it can be used without discomfort even if the concentration of o: -hydroxy acid is increased, and has a metabolic function without damaging the skin. Helps and keeps the skin beautiful and fresh.
  • content of the a-hydroxy acid can be increased, the improvement effect is enhanced and the improvement speed is also increased.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cosmetics (AREA)

Abstract

Cette invention concerne une composition dermatologique à trois composantes: un agent (A) renfermant, au moins comme principes actifs, au moins un amino-acide, un sel d'acide hyaluronique, un collagène hydro-soluble, du glycyrrhétinate de potassium, de l'allantoïne, une solution d'élastine hydrolysée et au moins un extrait de plante; un agent (B) renfermant, au moins comme principes actifs, au moins un acide α-hydroxy, de l'allantoïne et du glycyrrhétinate de potassium; et un agent (C) renfermant, au moins comme principe actif, un céramide et au moins un extrait de plante.
PCT/JP2001/001595 2001-03-01 2001-03-01 Composition dermatologique Ceased WO2002069913A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2002569091A JPWO2002069913A1 (ja) 2001-03-01 2001-03-01 皮膚改善用組成物セット
PCT/JP2001/001595 WO2002069913A1 (fr) 2001-03-01 2001-03-01 Composition dermatologique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/001595 WO2002069913A1 (fr) 2001-03-01 2001-03-01 Composition dermatologique

Publications (1)

Publication Number Publication Date
WO2002069913A1 true WO2002069913A1 (fr) 2002-09-12

Family

ID=11737087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/001595 Ceased WO2002069913A1 (fr) 2001-03-01 2001-03-01 Composition dermatologique

Country Status (2)

Country Link
JP (1) JPWO2002069913A1 (fr)
WO (1) WO2002069913A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004203855A (ja) * 2002-06-24 2004-07-22 Akira Awaya アレルギー性鼻炎・結膜炎あるいは皮膚アレルギーやアトピー性皮膚炎の予防・治療法
WO2007004300A1 (fr) * 2005-07-06 2007-01-11 Dr.Ci:Labo Co., Ltd. Produit cosmétique
JP2008056570A (ja) * 2006-08-29 2008-03-13 Fujifilm Corp 皮膚外用剤
US7399464B2 (en) 2001-06-11 2008-07-15 Genodyssee Sa Polypeptides of the IFNα-7 gene
JP2023539426A (ja) * 2020-07-31 2023-09-14 パン－モントージョ，フランシスコ グリコール酸とｌ－アラニンの薬学的組み合わせについて
KR102833334B1 (ko) * 2024-08-27 2025-07-14 주식회사 제이치컴퍼니 마그네슘 클로라이드 및 다양한 유용 성분을 포함하는 스프레이용 피부외용제 조성물 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508324A2 (fr) * 1991-04-10 1992-10-14 Ruey J. Dr. Yu Compositions contenant des acides 2-hydroxycarboxyliques et dérivés et méthodes pour atténuer les signes de vieilissement dermatologique
JPH07223934A (ja) * 1994-02-14 1995-08-22 Kanebo Ltd 皮膚化粧料
JPH07242529A (ja) * 1994-03-03 1995-09-19 Kanebo Ltd 皮膚化粧料

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508324A2 (fr) * 1991-04-10 1992-10-14 Ruey J. Dr. Yu Compositions contenant des acides 2-hydroxycarboxyliques et dérivés et méthodes pour atténuer les signes de vieilissement dermatologique
JPH07223934A (ja) * 1994-02-14 1995-08-22 Kanebo Ltd 皮膚化粧料
JPH07242529A (ja) * 1994-03-03 1995-09-19 Kanebo Ltd 皮膚化粧料

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399464B2 (en) 2001-06-11 2008-07-15 Genodyssee Sa Polypeptides of the IFNα-7 gene
JP2004203855A (ja) * 2002-06-24 2004-07-22 Akira Awaya アレルギー性鼻炎・結膜炎あるいは皮膚アレルギーやアトピー性皮膚炎の予防・治療法
WO2007004300A1 (fr) * 2005-07-06 2007-01-11 Dr.Ci:Labo Co., Ltd. Produit cosmétique
JPWO2007004300A1 (ja) * 2005-07-06 2009-01-22 株式会社ドクターシーラボ 化粧品
JP2008056570A (ja) * 2006-08-29 2008-03-13 Fujifilm Corp 皮膚外用剤
JP2023539426A (ja) * 2020-07-31 2023-09-14 パン－モントージョ，フランシスコ グリコール酸とｌ－アラニンの薬学的組み合わせについて
KR102833334B1 (ko) * 2024-08-27 2025-07-14 주식회사 제이치컴퍼니 마그네슘 클로라이드 및 다양한 유용 성분을 포함하는 스프레이용 피부외용제 조성물 제조방법

Also Published As

Publication number Publication date
JPWO2002069913A1 (ja) 2004-09-09

Similar Documents

Publication Publication Date Title
TWI352595B (en) Cosmetic and cosmeceutical compositions for restor
CN1663559B (zh) 皮肤健全剂
US20080183250A1 (en) Compositions and methods for treating or preventing skin inflammation via restoration of skin barrier function
CN105168040A (zh) 一种复合抗衰老护肤组合物及制作方法
CN113332160A (zh) 一种用于调理毛周角化肌肤的化妆品组合物
CN118021663A (zh) 一种头皮舒缓控油精华液
JP2016166236A (ja) 胎盤由来成分を含有するシワ改善用組成物
CN101146508A (zh) 恢复皮肤屏障功能的化妆品和药用化妆品组合物
WO2002069913A1 (fr) Composition dermatologique
CN110680761A (zh) 一种洗发水
CN107468610A (zh) 一种米糠壳的提取产物及其在面部护理的应用
KR100558751B1 (ko) 피부보습용 화장료 조성물
WO2002058640A1 (fr) Systeme therapeutique topique pour les soins de la peau
JP2006524199A (ja) 美容的ピーリング方法
CN117530902B (zh) 一种含硫酸酯化裂褶多糖的祛痘消炎组合物及其应用
JP5084831B2 (ja) 皮膚角質剥離用化粧料組成物
CN118105311A (zh) 一种具有祛皱功效的植物小分子肽组合物、制剂及其制备方法
KR20010090063A (ko) 머드(Mud) 팩의 조성물
CN115337243A (zh) 祛黑头组合物和化妆品
CN115836998A (zh) 一种美白祛皱长效保湿的方法
CN109453076A (zh) 一种含酵素的洁面慕丝及其制备方法
CN116549307A (zh) 一种安神舒缓型眼唇卸妆液及其制备方法
CN115887264A (zh) 一种含有硫辛酸联合富勒烯脂质体、精华液及其制备方法
JP2008088105A (ja) 皮膚若しくは毛髪用化粧料
CN115990122A (zh) 一种抗氧化和保湿修复面膜及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2002569091

Country of ref document: JP

122 Ep: pct application non-entry in european phase